Michael is Senior Vice President, Bridgehead USA Inc., and has extensive experience in developing pricing, market access, and commercial strategies for domestic and international pharmaceutical, biotech and medical device clients for both pipeline and in-line products.
Prior to joining Bridgehead, Michael was Principal, Pricing and Market Access Strategy at IMS Consulting, formerly known as Cambridge Pharma Consultancy. Before joining Cambridge, he ran his own life science-focused strategic consultancy and business development firm, which he formed after spending several years as a management consultant with A.T. Kearney in New York; Michael began his career in consulting at Deloitte Touche Tohmatsu Int'l in Japan.
Michael's expertise spans a number of therapeutic areas including oncology and oncology supportive care, cardiovascular, respiratory, Alzheimer's disease and other CNS areas, growth hormone, antivirals – including HIV, – surgical supportive care, and various hospital products, to name some. In addition to his extensive expertise in the US and Japanese markets, Michael has broad project experience in the major healthcare markets of Europe and Asia, as well as key emerging markets.
Michael holds a Bachelors degree in Natural Sciences/Biophysics from The Johns Hopkins University, a Masters in Public Health in Environmental Health Sciences from the Columbia School of Public Health and an MBA in Finance and International Business from the Columbia Business School. He speaks advanced Japanese, and is conversant in Chinese, French and German.
